Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

NCT06370065 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG: HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）

Sponsor

Tianjin Medical University Cancer Institute and Hospital